Market
Genomics funding activity
397 disclosed rounds across 272 companies in the last three years. Below: how they split by stage, which investors appear most often, and where the totals come from.
Peak 43 rounds in a quarter. Axis starts at zero.
The last three years
Computed from disclosed rounds. Figures update when the data does.
- 0
- Rounds
- 0
- Companies
- 0
- Rounds with an amount
- $8B
- Disclosed total
- $4M
- Median round
Where the money enters
Stage distribution over the same three years. A sector weighted to Pre-Seed and Seed is being formed; one weighted to later rounds is consolidating.
- Seed
- 17544%
- Series A
- 8421%
- Late Stage (Series C+)
- 7820%
- Pre-Seed
- 308%
- Series B
- 308%
Investors appearing most often
Ranked by number of rounds participated in, not by capital deployed — an accelerator writing 180 small cheques ranks above a fund writing four large ones, which is the right ranking when the question is who to approach.
- National Institutes of Health8 rounds
- ARCH Venture Partners5 rounds
- SOSV5 rounds
- SOSV SF & NY (Fka IndieBio)5 rounds
- Alumni Ventures5 rounds
- AdBio partners4 rounds
- Eos4 rounds
- Deep Track Capital4 rounds
Largest disclosed raisers
By disclosed amount across the period. Companies whose rounds carried no public amount cannot appear here however large the raise was.
- Tempus$1B
- CRISPR Therapeutics$830M
- Bionexus Gene Lab$500M
- Maze Therapeutics$415M
- Colossal Biosciences$391M
- Shiji Biotechnology$284M
- Tenpoint Therapeutics$235M
- EGenesis$191M
How to read these numbers
A company usually carries several sector tags, so its rounds count towards each. Sector totals therefore sum to more than the total number of rounds, and two sectors here can describe the same round.
Only rounds with a publicly disclosed amount contribute to totals and medians. Roughly a quarter of rounds carry no amount, and those are counted in the round count but never modelled into a figure.
A sector appears only with at least 100 rounds in the last three years. Below that the quarterly shape is noise, and a chart of noise is worse than no chart.
Related sectors
Work the underlying rounds, not the summary
This page is a fixed slice. In the product the same rounds are filterable by stage, geography and investor activity, and every investor here opens to their full participation history.